Arrowhead Pharmaceuticals Inc., of Pasadena, Calif., said it closed its private offering with investors, including Orbimed, RA Capital Management, Perceptive Advisors, RTW Investments and certain other institutional investors. About 7.63 million shares of common stock were issued at a price of $5.90 apiece. Gross proceeds totaled $45 million.